These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26054401)

  • 1. Requirements for benefit assessment in Germany and England - overview and comparison.
    Ivandic V
    Health Econ Rev; 2014 Dec; 4(1):12. PubMed ID: 26054401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 7. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Termination of Reimbursement of Arthroscopy in Osteoarthritis of the Knee: Is This Decision Based on Scientific Grounds?].
    Liebs TR; Berger S
    Z Orthop Unfall; 2017 Aug; 155(4):417-428. PubMed ID: 28675916
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies.
    Dundar Y; Dodd S; Dickson R; Walley T; Haycox A; Williamson PR
    Health Technol Assess; 2006 Feb; 10(5):iii-iv, ix-145. PubMed ID: 16487455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland.
    Lebioda A; Gasche D; Dippel FW; Theobald K; Plantör S
    Health Econ Rev; 2014 Dec; 4(1):31. PubMed ID: 26208931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimally invasive surgical procedures for the treatment of lumbar disc herniation.
    Lühmann D; Burkhardt-Hammer T; Borowski C; Raspe H
    GMS Health Technol Assess; 2005 Nov; 1():Doc07. PubMed ID: 21289928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.